Next-Generation Wound Dressings Trends, Technologies, And Insights

Executive Summary

The next generation wound dressings are evolving with the increasing prevalence of chronic wounds, and rising demand for effective home-based care. Emerging technologies such as hydrocolloid, foam, hydrogel, alginate, antimicrobial, sensor-integrated dressing, AI, and cloud-based platforms are transforming wound management by enabling real-time monitoring, personalized treatment, and more efficient care delivery.

Market Drivers

• Rising Prevalence of Chronic Wounds

The rising prevalence of chronic wounds, including diabetic foot ulcers, pressure ulcers, venous leg ulcers, and arterial ulcers, is driving significant growth in the wound dressing market. In October 2023, the Advances in Wound Care publication reported that chronic wounds affect 10.5 million U.S. Medicare beneficiaries, an increase of 2.3 million since 2014. These wounds impact the quality of life of nearly 2.5% of the total U.S. population, highlighting a significant public health concern. According to the American Diabetes Association, an estimated 537 million people worldwide have diabetes, and 19% to 34% of these individuals are expected to develop a diabetic foot ulcer in their lifetime.

This growing demand encourages innovation in developing innovative, antimicrobial, bioactive dressings, and sensor-integrated and AI-enabled technologies. As a result, companies are investing in research and clinical trials to enhance healing outcomes, reduce infection risks, and improve the quality of life for patients with chronic wounds.

• Prevalence and Prevention of Hospital-Acquired Pressure Injuries in Omani Critical Care Units (2024)

• Increasing Focus on Clinical Trials

Increasing focus on clinical trials is a key driver of advancements in wound dressings, as it provides robust evidence of safety and efficacy, supports regulatory approvals, and accelerates the adoption of innovative materials and smart technologies in clinical practice. Ongoing trials enable the optimization of dressings formulations and personalized therapies, ensuring better healing outcomes for diverse patient populations.

Below is a table summarizing a few of the recently completed or ongoing studies in this field.

Source: ClinicalTrials.gov

Competitive Scenario

Some of the key players operating in the next generation wound dressings include:

• Scapa

• Axio Biosolutions Pvt Ltd

• Smith+Nephew

• AVERY DENNISON CORPORATION

• MEDCu

• Mölnlycke AB

• Convatec Inc.

• 3M

• Triage Meditech Pvt. Ltd

• Advamedica Inc

Recent Developments

Some of the strategies undertaken by key industry players operating in the advancements in wound dressings market are mentioned below:

• In March 2025, Mölnlycke Health Care launched Mepilex Border Flex, a multi-layered silicone-coated foam dressing designed to improve chronic wound care. Dressing enhances conformability and exudate management, reduces dressing-related complications, and promotes faster healing and patient comfort.

• In September 2025, Advamedica Inc. received FDA 510(k) clearance and HCPCS code approval for MaxioCel, its advanced wound care dressing made from 100% chitosan. The approval expands its availability in the U.S., complementing over five years of use in Europe and other countries. MaxioCel is designed to manage moderate to heavily exuding wounds, maintaining a moist healing environment and supporting easy removal.

In June 2023, JeNaCell, an Evonik company, launched the epicite balance wound dressing in Germany. Made from biosynthetic cellulose, it supports healing of chronic wounds with low to medium exudate by maintaining a moist environment, and is suitable for conditions like venous leg ulcers, diabetic foot ulcers, and pressure ulcers.